



CLEARSIDE[™] BIOMEDICAL

Financial Tear Sheet

Corporate Profile


Clearside Biomedical, Inc. is a clinical-stage biopharmaceutical company developing first-in-class drug therapies to treat chronic, blinding diseases of the eye.

Stock Performance

CLSD (COMMON STOCK)

Exchange	NASDAQ GS (US Dollar)
Price	\$9.37
Change (%)	▲ 0.11 (1.19%)
Volume	41,050
52 Week Low	\$5.44
Market Cap	\$234,278,148
Rolling EPS	-1.18
PE Ratio	0
Shares Outstanding	25,300,016

Data as of 06/28/17 12:36 p.m. ET



Recent Headlines

06/13/17

Clearside Biomedical, Inc. to Participate in 2017 JMP Securities Life Sciences Conference

06/08/17

Clearside Biomedical's TANZANITE Extension Study in Patients with Macular Edema Associated with Retinal Vein Occlusion Presented at the 40th Annual Macula Society Meeting

05/10/17

Clearside Biomedical, Inc. Announces First Quarter 2017 Financial Results and Provides Corporate Update

Upcoming Events

There are currently no events scheduled.

SEC Filings

FILING DATE	FORM
06/23/17	4
06/23/17	4
06/23/17	4
06/23/17	4

Corporate Governance

Daniel H. White	President and Chief Executive Officer
Rafael V. Andino	Vice President, Engineering and Manufacturing
Charles A. Deignan	Chief Financial Officer
Stephen H. Lang	Vice President, Commercial Operations
Glenn Noronha, Ph.D.	Executive Vice President, Research and Development

Data provided by Nasdaq. Minimum 15 minutes delayed. [View Attributions and Sources](#)